company background image
GOVX logo

GeoVax Labs NasdaqCM:GOVX Stock Report

Last Price

US$2.36

Market Cap

US$4.2m

7D

0%

1Y

-76.6%

Updated

27 Feb, 2024

Data

Company Financials +

GOVX Stock Overview

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform.

GOVX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

GeoVax Labs, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GeoVax Labs
Historical stock prices
Current Share PriceUS$2.36
52 Week HighUS$11.85
52 Week LowUS$2.04
Beta2.94
1 Month Change-44.50%
3 Month Change-63.41%
1 Year Change-76.60%
3 Year Change-96.91%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Recent updates

We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

Sep 08
We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

GeoVax: Possible Vaccine Advancements In 2 Big Indications

Aug 08

GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine

Jul 28

Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky

May 24
Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

Dec 27

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Nov 27
We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Oct 03

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Aug 14
We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?

Feb 18
Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?

GeoVax soars on NIAID grant for COVID-19 vaccine candidate

Jan 11

Shareholder Returns

GOVXUS BiotechsUS Market
7D0%3.4%1.8%
1Y-76.6%10.7%25.1%

Return vs Industry: GOVX underperformed the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: GOVX underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is GOVX's price volatile compared to industry and market?
GOVX volatility
GOVX Average Weekly Movement10.3%
Biotechs Industry Average Movement11.6%
Market Average Movement6.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: GOVX's share price has been volatile over the past 3 months.

Volatility Over Time: GOVX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
198814David Doddhttps://www.geovax.com

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

GeoVax Labs, Inc. Fundamentals Summary

How do GeoVax Labs's earnings and revenue compare to its market cap?
GOVX fundamental statistics
Market capUS$4.20m
Earnings (TTM)-US$23.76m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GOVX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$18.25m
Gross Profit-US$18.25m
Other ExpensesUS$5.51m
Earnings-US$23.76m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 29, 2024

Earnings per share (EPS)-13.35
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GOVX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.